ReviewExpert review of neurotherapeutics2009
Management of the patient with medically refractory epilepsy.
Review in Expert review of neurotherapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 14 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Ketogenic diet therapies for the treatment of drug-resistant epilepsy in children and adults: A systematic review.PloS one · 2026Pooled it
- Adjunctive treatment for pediatric focal epilepsy: a systematic review.European journal of clinical pharmacology · 2025Pooled it
- Stiripentol add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2022Pooled it
- Felbamate add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2022Pooled it
- Pregabalin add-on for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2022Pooled it
- Rufinamide add-on therapy for drug-resistant epilepsy.The Cochrane database of systematic reviews · 2020Pooled it
- Ketogenic diets for drug-resistant epilepsy.The Cochrane database of systematic reviews · 2020Pooled it
- Stiripentol add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2020Pooled it
- Felbamate add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2019Pooled it
- Pregabalin add-on for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2019Pooled it
- Ketogenic diets for drug-resistant epilepsy.The Cochrane database of systematic reviews · 2018Pooled it
- Stiripentol add-on therapy for focal refractory epilepsy.The Cochrane database of systematic reviews · 2018Pooled it
- Rufinamide add-on therapy for refractory epilepsy.The Cochrane database of systematic reviews · 2018Pooled it
- Felbamate as an add-on therapy for refractory partial epilepsy.The Cochrane database of systematic reviews · 2017Pooled it
- Optimization of cortico-cortical spectral response analysis parameters for seizure onset zone localization.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2026Article
- Eigenvector biomarker for prediction of epileptogenic zones and surgical success from interictal data.Frontiers in network physiology · 2025Article
- Network excitability of stimulation-induced spectral responses helps localize the seizure onset zone.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2024Article
- Alterations of apparent diffusion coefficient from ultra high b-values in the bilateral thalamus and striatum in MRI-negative drug-resistant epilepsy.Epilepsia open · 2024Article
- The Metabolic Role of Ketogenic Diets in Treating Epilepsy.Nutrients · 2022Review
- Stimulating native seizures with neural resonance: a new approach to localize the seizure onset zone.Brain : a journal of neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Epilepsy imposes a significant clinical, epidemiologic and economic burden on societies throughout the world. Despite the development of more than ten new antiepileptic drugs over the past 15 years, approximately a third of patients with epilepsy remain resistant to pharmacotherapy. Individuals who fail to respond, or respond only partially, continue to have incapacitating seizures. Managing patients with medically refractory epilepsy is challenging and requires a structured multidisciplinary approach in specialized clinics. If the problems related to drug resistance could be resolved, even in part, by improving the pharmacokinetic profile of existing drugs, the economic savings would be remarkable and the time required to design drugs that achieve seizure control would be shorter than the discovery of new targets and molecules was required. A promising approach is the use of corticosteroids that may have a dual beneficial effect. Resective brain surgery remains the ultimate and highly successful approach to multiple drug resistance in epileptic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.